# Enhancing the Efficacy of CAR-T Cell Production Using BX795 and Rosuvastatin in a Serum-Free Medium

## TL;DR

This paper presents a new method to improve CAR-T cell production using a serum-free medium and specific additives, which could lead to better cancer immunotherapy outcomes.

## Contribution

The study introduces a novel combination of BX795 and rosuvastatin in a serum-free medium to enhance CAR-T cell transduction and functionality.

## Key findings

- Using Nutri-T medium with BX795 and rosuvastatin improves CAR-T cell transduction efficiency.
- The proposed method enhances the functionality and persistence of CAR-T cells in vitro.

## Abstract

Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a transformative approach for cancer treatment, demonstrating remarkable success in patients with relapsed and refractory hematological malignancies. However, challenges persist in optimizing CAR-T cell production and improving therapeutic outcomes. One of the major hurdles is the efficiency of retroviral or lentiviral transduction during CAR-T cell manufacturing. Additionally, the heterogeneity of T-cell populations isolated from patients can impact CAR-T cell effectiveness and persistence in vivo. This article explores a novel strategy to address these challenges by focusing on serum-free medium and additive optimization. We propose a unique approach that incorporates the culturing of T cells in Nutri-T medium, along with 24 h of exposure to combined low concentrations of BX795 and rosuvastatin, to enhance the transduction efficacy and functionality of CAR-T cells. The results presented here provide promising insights into the potential of this strategy to produce more effective CAR-T cells for immunotherapy, ultimately advancing the field and benefiting cancer patients worldwide.